Clinical trials
Hepatitis D, Chronic clinical trials
Below are recruiting hepatitis d, chronic clinical trials, each written for real people, not researchers. We’re tracking 42 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07179575RecruitingPhase 1/Phase 2
Study of LW231 for people with chronic hepatitis B
This trial tests a new drug, LW231, in people with chronic hepatitis B. It aims to see if the drug can reduce the amount of virus and surface antigen in your blood, and if it is safe for you.
Hangzhou, ZhejiangAges 18–60 - NCT07024641RecruitingPhase 1
Safety study of GIGA-2339 for chronic Hepatitis B
This study tests an experimental antibody (GIGA-2339) given as an infusion to people with chronic Hepatitis B. It aims to see if the drug is safe and how the body processes it, possibly helping to control the virus.
Chandler, ArizonaAges 18 years+ - NCT03097952Recruiting
Study of people with long-term hepatitis B in real life
This “real-life” study follows people with chronic hepatitis B to better understand their health over time. It may help researchers learn which factors affect outcomes in everyday care.
Changzhou, JiangsuAges Any age - NCT06504485Recruiting
Study of bulevirtide for chronic hepatitis B and D
This trial tests a drug called bulevirtide for people with chronic hepatitis B and D (HDV) co-infection. It looks at how the immune system and virus respond to treatment.
MilanAges 18 years+ - NCT05195450Recruiting
Tenofovir to stop liver disease in mild hepatitis B
This trial tests tenofovir alafenamide (a hepatitis B antiviral medicine) to see if it can prevent liver disease from getting worse in people with chronic hepatitis B who currently have stable (normal) liver blood tests and low virus levels. It may help lower the chance of developing serious liver complications over time.
New Delhi, National Capital Territory of DelhiAges 18–70 - NCT05255978Recruiting
Follow-up study for hepatitis B with fatty liver
This observational study looks at people with chronic hepatitis B who also have fatty liver (non-alcoholic fatty liver disease). It follows how their liver health changes over time and may help doctors understand outcomes and risk factors.
Wuhan, HubeiAges 18 years+ - NCT05661786Recruiting
Study outcomes for hepatitis B with “indeterminate” disease phase
This trial studies what happens to people with hepatitis B who have hepatitis B surface antigen for more than 6 months, are “HBeAg-negative,” and have certain blood and liver-scarring levels despite normal or near-normal liver inflammation. It may help doctors understand the best care for this specific group before clear treatment phases.
Changzhou, JiangsuAges 18 years+ - NCT05583006Recruiting
Switch from entecavir to tenofovir for chronic hepatitis B
This trial studies switching people with chronic hepatitis B from entecavir (ETV) to tenofovir alafenamide (TAF). It may help if you feel your current entecavir treatment isn’t working well enough or is inconvenient.
Taichung, TaiwanAges 20 years+ - NCT07429864Recruiting
Bulevirtide for hepatitis D: bile acids and gut bacteria
This study looks at how Bulevirtide, a treatment for hepatitis D, affects bile acids and gut bacteria. It may help patients with chronic HDV and stable liver disease who are already on HBV therapy.
RomaAges 18 years+ - NCT07275918RecruitingPhase 1
Study of SA1211 injection for chronic hepatitis B
This study tests a new injection called SA1211 for people with chronic hepatitis B. It will help see if the treatment is safe and how it works in the body.
Changchun, JilinAges 18–65 - NCT06889805Recruiting
HDV screening for HIV and hepatitis B patients
This study tests whether people with both HIV and chronic hepatitis B should be checked for a third liver virus called HDV (hepatitis D). It helps find hidden infections so they can get the right care.
Hong KongAges 18 years+ - NCT05937178Recruiting
Real-World Study to Optimize Hepatitis B Tablet Treatment
This study looks at how to best use existing hepatitis B “nucleotide-analog” tablets in everyday care. It may help tailor when to start, and whether to continue or adjust treatment, based on your test results.
Hefei, AnhuiAges 18–80 - NCT06923280Recruiting
Sequential Pegylated Interferon After RNA-Targeted Hepatitis B Therapy
This trial tests a sequence of pegylated interferon (PEG-IFN) shots for people with chronic hepatitis B who have already had a significant drop in their virus levels after taking a newer type of RNA-targeting medicine. The goal is to see if this approach can help clear the virus even further.
Beijing, ChinaAges 18–80 - NCT07581756Recruiting
Brain Stimulation Treatment for Diarrhea-Prone Irritable Bowel Syndrome
This trial tests whether repeated magnetic stimulation applied to the scalp (a non-invasive procedure) can reduce diarrhea and belly pain in people with diarrhea-predominant IBS. The goal is to see if this brain-based treatment can improve your symptoms.
Suzhou, JiangsuAges 18–70 - NCT06454669RecruitingPhase 2
Dronabinol added to opioids for chronic low back pain
This trial tests whether adding dronabinol (a prescription medication derived from cannabis) to your current opioid pain treatment can help reduce chronic low back pain more effectively. It is for people who have had persistent low back pain for at least 3 months and are already on a stable opioid regimen.
Houston, TexasAges 18–64 - NCT05877846Recruiting
Personalized care to improve physical function in older adults
This study looks at precision (personalized) approaches to help older adults improve physical function. It may include giving a specific supplement depending on lab results, and it requires regular study visits and ability to complete procedures.
Chapel Hill, North CarolinaAges 65–85 - NCT07607197RecruitingPhase 1/Phase 2
Immune Reset to Help Highly Sensitized Kidney Transplant Patients
This study tests whether a special immune-resetting treatment can help patients who have developed too many antibodies against donor kidneys get access to a compatible kidney transplant. The treatment uses chemotherapy and stem cell transplantation to 'reset' your immune system so it stops rejecting potential donor kidneys.
Barcelona, CataloniaAges 18–60 - NCT07564739Recruiting
Cold Plasma Treatment for Long-Lasting Wound Healing
This study tests whether a special cold plasma treatment (a type of energized gas) can safely help heal chronic wounds that haven't improved after several weeks. Cold plasma may help clean wounds and reduce bacteria, potentially speeding up healing.
OrléansAges 18 years+
Hear when a new Hepatitis D, Chronic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for hepatitis d, chronic?
- Yes. Clin2 currently lists 42 recruiting hepatitis d, chronic studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a hepatitis d, chronic trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a hepatitis d, chronic trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.